Abstract
BackgroundUrothelial cancers are immunogenic and may benefit from anti-PD1/PDL1 no matter in front-line cisplatin-ineligible patients(IMvigor210) or 2nd line setting(KN45). Avelumab maintenance after 1st line platinum-based chemotherapy(JAVELIN Bladder 100) in 1st...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
